Background The novel coronavirus SARS-CoV2 that causes COVID-19 has resulted in the death of more than 2.5 million people, but no cure exists. Although passive immunization with COVID-19 convalescent plasma (CCP) provides a safe and viable therapeutic option, the selection of optimal units for therapy in a timely fashion remains a barrier. Study design and methods Since virus neutralization is a necessary characteristic of plasma that can benefit recipients, the neutralizing titers of plasma samples were measured using a retroviral-pseudotype assay. Binding antibody titers to the spike (S) protein were also determined by a clinically available serological assay (Ortho-Vitros total IG), and an in-house ELISA. The results of these assays were compared to a measurement of antibodies directed to the receptor binding domain (RBD) of the SARS-CoV2 S protein (Promega Lumit Dx). Results All measures of antibodies were highly variable, but correlated, to different degrees, with each other. However, the anti-RBD antibodies correlated with viral neutralizing titers to a greater extent than the other antibody assays. Discussion Our observations support the use of an anti-RBD assay such as the Lumit Dx assay, as an optimal predictor of the neutralization capability of CCP.
【초록키워드】 COVID-19, convalescent plasma, passive immunization, SARS-CoV2, therapy, S protein, antibody, neutralization, immunization, Novel coronavirus, Receptor binding domain, Protein, Viral, Serological assay, RBD, Antibody titer, Virus neutralization, death, Study design, plasma, characteristic, Antibody titers, Antibody assays, Neutralizing titer, anti-RBD, barrier, Safe, Anti-RBD antibody, CCP, therapeutic option, determined by, Support, observation, Promega, recipients, house, in-house ELISA, plasma samples, measure, Anti-RBD antibodies, neutralizing titers, total Ig, SARS-CoV2 S protein, benefit, plasma sample, Result, greater, clinically, provide, correlated, cause, were measured, with COVID-19, 【제목키워드】 COVID-19, Efficacy, Donor, binding domain,